Regulus Reports Fourth Quarter and Year-End 2015 Financial Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Regulus Therapeutics (RGLS) Tops Q4 EPS by 11c
February 22, 2016 4:29 PM ESTRegulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $10.9 million versus the consensus estimate of $5.09 million.
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
... More